Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions.

Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier.

Our name reflects our expertise: “ipso” means “self” and “med” stands for medication. As such, our company name perfectly illustrates our core business: to market our innovative, high-quality, and reliable products and services that enable patients to administer their own medication safely and easily. With our injection and infusion systems and related services, we support millions of people with chronic conditions all over the world in enjoying the best possible quality of life.

We develop and produce customized injection systems. Our portfolio ranges from simple disposable pens to pens with variable dosing and electronic displays, all the way to highly complex injectors featuring multifunctional electronics.

We strive for long-term, trust-based relationships with our business partners, characterized by openness and reliability.

Ypsomed Holding AG is organized as a holding company under Swiss law and directly or indirectly owns all companies worldwide that are part of the Ypsomed Group. The subsidiaries held by Ypsomed Holding AG are not publicly listed.